Asia Pacific Anticoagulant Reversal Drug Market Size, Share, and Analysis by 2027

The anticoagulant reversal drug market in Asia Pacific is expected to grow from US$ 173.5 million in 2019 to US$ 444.8 million by 2027; it is estimated to grow at a CAGR of 13.2% from 2019 to 2027.

Oral anticoagulants are widely used and are highly effective in preventing thromboembolism among AFib patients. However, the use of anticoagulants may lead to bleeding in AFib patients; thus, anticoagulant reversal drugs are used to prevent bleeding. According to the report "Beyond the Burden: The Impact of Atrial Fibrillation in Asia Pacific," from Biosense Webster (part of Johnson & Johnson Medical Devices Companies), atrial fibrillation is projected to affect around 72 million people in Asia Pacific by 2050. This report was launched at the annual meeting of Asia Pacific Rhythm Society (APHRS) in Bangkok. The report studied the current state of atrial fibrillation in Asia, as well as future projections for the medical condition. The report also mentioned that the number of patients diagnosed with atrial fibrillation increases by 1.4 million every year. Thus, such high prevalence of atrial fibrillation is likely to favor the growth of the market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the anticoagulant reversal drugs market. The Asia Pacific anticoagulant reversal drugs market is expected to grow at a good CAGR during the forecast period.

Asia Pacific Anticoagulant Reversal Drug Market Segmentation           

By Product

• Prothrombin Complex Concentrates
• Vitamin K
• Protamine
• Tranexamic Acid
• Idarucizumab
• AndeXXa

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Country

• Asia Pacific

  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of Asia Pacific

Companies Mentioned

• Boehringer Ingelheim International GmbH
• Pfizer Inc
• Octapharma AG
• Fresenius Kabi AG
• Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
• CSL Limited
• Grifols, S.A.
• China Biologic Products, Inc
• Shanghai RAAS Blood Products Co., Ltd.

Asia Pacific Anticoagulant Reversal Drug Report Scope